TY  - JOUR
AU  - Sawicki, Lino M.
AU  - Buchbender, Christian
AU  - Boos, Johannes
AU  - Giessing, Markus
AU  - Ermert, Johannes
AU  - Antke, Christina
AU  - Antoch, Gerald
AU  - Hautzel, Hubertus
TI  - Diagnostic potential of PET/CT using a $^{68}$Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience
JO  - European journal of nuclear medicine and molecular imaging
VL  - 44
IS  - 1
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - FZJ-2016-07117
SP  - 102 - 107
PY  - 2017
AB  - Purpose To evaluate the diagnostic potential of whole-bodyPET/CT using a 68Ga-labelled PSMA ligand in renal cell carcinoma(RCC).Methods Six patients with histopathologically proven RCCunderwent 68Ga-PSMA PET/CT. Each PET/CT scan wasevaluated in relation to lesion count, location and dignity.SUVmax was measured in primary tumours and PETpositivemetastases. Tumour-to-background SUVmax ratios(TBRSUVmax) were calculated for primary RCCs in relationto the surrounding normal renal parenchyma. Metastasis-tobackgroundSUVmax ratios (MBRSUVmax) were calculatedfor PET-positive metastases in relation to gluteal muscle.Results Five primary RCCs and 16 metastases were evaluated.The mean SUVmax of the primary RCCs was 9.9 ± 9.2(range 1.7 – 27.2). Due to high uptake in the surrounding renalparenchyma, the mean TBRSUVmax of the primary RCCs wasonly 0.2 ± 0.3 (range 0.02 – 0.7). Eight metastases showed focal68Ga-PSMA uptake (SUVmax 9.9 ± 8.3, range 3.4 – 25.6).The mean MBRSUVmax of these PET-positive metastases was11.7 ± 0.2 (range 4.4 – 28.1). All PET-negative metastaseswere subcentimetre lung metastases.Conclusion 68Ga-PSMA PET/CT appears to be a promisingmethod for detecting RCC metastases. However, no additionaldiagnostic value in assessing the primary tumour was found.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000389242200013
C6  - pmid:26996777
DO  - DOI:10.1007/s00259-016-3360-2
UR  - https://juser.fz-juelich.de/record/824545
ER  -